PRODUCT LITERATURE

Breast Cancer: High-Dose Therapy

---

Breast cancer has become the leading indication for high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) in North America. The rapid increase in HDC/ASCR for breast cancer has been driven by belief in the response rates and survival times demonstrated in phase II studies, which
have been higher than that of historical controls. However, there is a growing body of data to suggest that selection bias has had a significant impact on the
outcome of non-randomized studies of HDC. Few randomized comparisons of HDC to standard-dose chemotherapy exist.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Epirubisin

Specific Detail Info

The Oncologist 1998;3:289-299

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment